XST-14

SKU: orb1689422

Description

XST-14 is a potent and selective ULK1 inhibitor (IC50: 26.6 nM) that suppresses autophagy by blocking downstream substrate phosphorylation. It demonstrates anti-tumor activity by inducing apoptosis and inhibiting the proliferation of hepatocellular carcinoma cells in vitro.

Research Area

Cardiovascular Research, Cell Biology, Neuroscience, Signal Transduction, Stem Cell & Developmental Biology

Key Properties

• CAS Number: 2607143-50-8
• MW: 291.34
• Purity: 99.84% (May vary between batches)
• Formula: C₁₆H₂₁NO₄
• SMILES: COC(=O)c1cc2c(OC(C)C)cc(OC(C)C)cc2[nH]1
• Target: CaMK,p38 MAPK,Apoptosis,ALK,TGF-beta/Smad,Autophagy
• Solubility: DMSO:80 mg/mL (274.59 mM)

Bioactivity

• Target IC50:
  ULK1:26.6 nM
• In Vivo:
  BALB/c mice were treated with XST-14 (30 mg/kg, IP, every other day), sorafenib (30 mg/kg, P.O), or a combination of sorafenib (30 mg/kg, P.O) and XST-14 (30 mg/kg, IP) for 2 weeks. The results indicate that XST-14 exhibits favorable drug metabolism and pharmacokinetic (DMPK) properties, with no significant toxicity observed on liver/kidney function or body weight.
  Read more...
• In Vitro:
  Treatment of HepG2 cells with XST-14 (5 μM) alone or in combination with sorafenib (5 μM) for 24 hours showed a synergistic effect, indicating that XST-14 in combination with sorafenib can inhibit HCC in vitro.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

Autophagy, Apoptosis, ULK1

Compound Identifiers

PubChem CID

155291452